🕵️ Aktis Oncology, Inc. ($AKTS)
SEC insider & ownership activity, last 12 months · CIK 2035832 · every row links its SEC filing
Over the last 12 months insiders sold $3.0M against $114.3M of open-market buying. ECOR1 Capital, LLC bought $40.0M in discretionary trades (Jan). 1 planned sale is pending, the largest $77K (Ken Herrmann). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
6 buyers, $114.3M (9 lots) · 3 sellers, $3.0M (9 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| ECOR1 Capital, LLC | 2 | $40.0M | 0 | – | Jan 12, 2026 |
| Ansbert Gadicke | 1 | $20.0M | 0 | – | Jan 12, 2026 |
| MPM Bioventures 2018, L.P. | 1 | $20.0M | 0 | – | Jan 12, 2026 |
| VIDA Ventures II, LLC | 2 | $15.0M | 0 | – | Jan 12, 2026 |
| Helen Kim | 2 | $15.0M | 0 | – | Jan 12, 2026 |
| Todd Foley | 1 | $4.2M | 0 | – | Jan 12, 2026 |
| Czibere Akos | 0 | – | 3 | $1.4M | Jul 8, 2026 |
| Ron-Bigger Shulamit | 0 | – | 3 | $1.4M | Jul 8, 2026 |
| Herrmann Ken | 0 | – | 3 | $197K | Jul 20, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Ansbert Gadicke | 19.3% | 13D | Jan 12, 2026 | filing ↗ | |
| Eli Lilly and Company | 11.9% | 13D | Jan 12, 2026 | filing ↗ | |
| VV Manager II LLC | 10.9% | 13D | Jan 12, 2026 | filing ↗ | |
| Helen Kim | 10.9% | 13D | Jan 12, 2026 | filing ↗ | |
| VIDA Ventures II, LLC | 10.6% | 13D | Jan 12, 2026 | filing ↗ | |
| Luke Evnin | 9.5% | 13D | Jan 12, 2026 | filing ↗ | |
| MPM Oncology Investments 2 LLC | 9.1% | 13D | Jan 12, 2026 | filing ↗ | |
| Oncology Impact Private Investment Fund 2, L.P. | 9.1% | 13D | Jan 12, 2026 | filing ↗ | |
| ECOR1 Capital, LLC | 9.1% | 13D | Jan 12, 2026 | filing ↗ | |
| Oleg Nodelman | 9.1% | 13D | Jan 12, 2026 | filing ↗ | |
| ECOR1 Capital Fund Qualified, L.P. | 8.2% | 13D | Jan 12, 2026 | filing ↗ | |
| Todd Foley | 8.0% | 13D | Jan 12, 2026 | filing ↗ | |
| MPM Bioventures 2018 LLC | 7.9% | 13D | Jan 12, 2026 | filing ↗ | |
| MPM Bioventures 2018 GP LLC | 7.8% | 13D | Jan 12, 2026 | filing ↗ | |
| MPM Bioventures 2018, L.P. | 7.4% | 13D | Jan 12, 2026 | filing ↗ | |
| Blue OWL Capital Holdings LP | 5.9% | 13G | May 14, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Ken Herrmann | $119K | Jul 20, 2026 | filing ↗ |
| Ken Herrmann | $77K | Jul 17, 2026 | filing ↗ |
| Akos Czibere | $1.4M | Jul 8, 2026 | filing ↗ |
| Shulamit Ron-Bigger | $1.4M | Jul 8, 2026 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Earnings (2.02) | May 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 11, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 15, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 15, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 15, 2026 | filing ↗ |
| Earnings (2.02) | Mar 30, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 30, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Jan 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 12, 2026 | filing ↗ |